What Was Known Before {#section18-2054358116679131}
=====================

The concept of incremental peritoneal dialysis (PD) has been discussed for almost 2 decades, but there is no literature describing its use in a large contemporary PD program.

What This Adds {#section19-2054358116679131}
==============

This study shows that it is feasible to practice incremental PD in a large contemporary patient population and that target clearances can be achieved with less onerous and less expensive PD prescriptions.

Introduction {#section20-2054358116679131}
============

Incremental dialysis is the practice of initiating chronic dialysis with low clearance prescriptions, relying on the presence of significant residual renal function to ensure clearance targets are achieved. It was first defined in the 1997 National Kidney Foundation Dialysis Outcome Quality Initiative Guideline on Peritoneal Dialysis Adequacy and was initially discussed more as a concept than as an actual practice, with the idea being that it would be associated with earlier initiation of chronic PD.^[@bibr1-2054358116679131][@bibr2-2054358116679131][@bibr3-2054358116679131]-[@bibr4-2054358116679131]^ The underlying aim is to make the initial dialysis prescription less onerous for the patient. Typical initial incremental dialysis prescriptions include twice weekly hemodialysis or cycler PD without a day dwell. The strategy is attractive because it reduces costs and decreases workload for patients and their caregivers. Implicit in the practice is the idea that, as patients lose their residual renal function, their dialysis dose will be raised in order that they stay at or slightly above clearance targets.^[@bibr1-2054358116679131]^

Incremental PD has been discussed in the literature for many years. A number of articles, mainly from Italy, have described its use in small numbers of patients, mostly treated with continuous ambulatory PD (CAPD).^[@bibr5-2054358116679131][@bibr6-2054358116679131][@bibr7-2054358116679131][@bibr8-2054358116679131]-[@bibr9-2054358116679131]^ A survey of North American PD centers in 1999 suggested it was being used by a significant number of PD practitioners.^[@bibr10-2054358116679131]^ Its potential relevance increased with the worldwide tendency in the 1990s and 2000s to initiate chronic dialysis at higher levels of renal function as this provides greater margin for its use.^[@bibr11-2054358116679131],[@bibr12-2054358116679131]^ However, no large-scale experience with the approach has been reported and what it actually means to apply it in clinical practice is not well described or widely understood.

Our center has practiced incremental PD routinely in all patients for the past decade. We review here, in a cross-sectional manner, our experience in a large contemporary patient population treated predominantly with automated PD (APD). Our aim is to describe what incremental PD means in terms of the types of PD prescriptions required and the clearances achieved.

Methods {#section21-2054358116679131}
=======

Setting {#section22-2054358116679131}
-------

The London Health Sciences Centre PD Program is based at an academic medical center in South Western Ontario, Canada. It serves a population of approximately 1.2 million people and is part of a comprehensive renal replacement treatment program that also includes in-center, satellite, and home hemodialysis, as well as kidney transplantation.

Study Population {#section23-2054358116679131}
----------------

PD patients are trained in CAPD and then APD and can choose which modality they prefer. The program uses Baxter Twin Bag (Baxter Deerfield, Illinois) for CAPD and Home Choice Pro Cycler (Baxter Deerfield) for APD.

In mid-2013, we collected data on all 124 patients who were on PD at that time. We recorded basic demographic data, their exact PD prescription, and their most recent peritoneal, renal, and total urea clearances, normalized to total body water (fractional urea clearance \[Kt/V\]). The practice at the time was to measure peritoneal, renal, and total Kt/V at least once every 3 months. In accordance with Canadian Society of Nephrology guidelines, the target total Kt/V is 1.7 per week, although we also use clinical judgment to avoid excessively onerous PD prescriptions, especially in elderly, frail patients where the disadvantages of a rigid approach might outweigh the potential benefits.^[@bibr13-2054358116679131]^

Definitions {#section24-2054358116679131}
-----------

For the purposes of the study, a patient was defined as doing "Incremental PD" if they had a peritoneal Kt/V less than 1.7 per week and a total Kt/V of 1.7 per week or greater and *any one of the following*: (1) a CAPD with less than 8-L PD solution daily, (2) a CAPD for less than 7 days a week, (3) APD without any day dwell, or (4) APD for less than 7 days a week. This definition is derived from the 1997 National Kidney Foundation Dialysis Outcome Quality Initiative Guideline on Peritoneal Dialysis Adequacy although the Kt/V target is now lower than it was then.^[@bibr1-2054358116679131],[@bibr13-2054358116679131]^ "Full-Dose PD" was defined as CAPD with at least 8 L daily or APD with a cycler treatment every night and with at least 1 day dwell each day. This was also based on the 1997 Guideline and on widely used PD practices in Canada in previous surveys.^[@bibr14-2054358116679131]^ It is recognized that standard PD prescriptions may differ between countries.^[@bibr15-2054358116679131]^ These "Full-Dose PD" patients can be subdivided into those who achieve the Kt/V target with peritoneal Kt/V alone and those who achieve it through a combination of both peritoneal and residual renal clearance.

Outcome Measures {#section25-2054358116679131}
----------------

The outcome of interest here was the proportion of patients who achieved the target clearance with an incremental PD strategy. Clearances are measured in the conventional manner.^[@bibr13-2054358116679131]^ Renal urea clearance is calculated by collecting a 24-hour urine, measuring its urea content and dividing by the daytime blood urea. This value is normalized to total body water, estimated using the Watson formula, based on age, sex, and weight, to give a renal Kt/V. In this calculation, we use the standardized or "nonobese" weight, rather than the actual weight, as suggested by Canadian Society of Nephrology guidelines.^[@bibr13-2054358116679131]^ This is based on the rationale that body fat has low water content and does not require the same amount of clearance as lean body mass. Residual renal clearance is also estimated in the standard manner using the mean of renal urea and renal creatinine clearance with normalization to body surface area calculated using the DuBois formula.^[@bibr13-2054358116679131]^

Peritoneal urea clearance is calculated in CAPD patients by performing a 24-hour effluent collection and by measuring its urea content. In APD patients, a 24-hour effluent collection is not practical and cycler effluent volume is estimated by adding the known prescribed volume of PD solution to the ultrafiltration volume as recorded by the cycler. A 10-mL sample of the cycler effluent taken by the patient after careful mixing of the effluent in a single container is sent for measurement of urea concentration, and total effluent urea content can thus be estimated. Any additional effluent volume from "manually" performed day dwells is collected and its urea content added to give to the total 24-hour effluent urea content. In both CAPD and APD, the effluent urea content is divided by the daytime blood urea to give peritoneal urea clearance and again normalization to total body water gives a peritoneal Kt/V. While both renal and peritoneal Kt/V are measured over 1 day, they are expressed per week, as is the convention for Kt/V in PD.^[@bibr13-2054358116679131]^ The actual calculations are carried out using Baxter PD Adequest (Baxter Deerfield).

Program outcomes were assessed by looking at peritonitis rates, patient survival, and by proportion of patients meeting the Kt/V target of 1.7 per week. Peritonitis rates are calculated annually using POET software (Baxter Deerfield).^[@bibr16-2054358116679131]^ Patient survival is calculated for each center in Canada by the Canadian Organ Replacement Register and compared with the rates for the country as a whole.

Statistical Analysis {#section26-2054358116679131}
--------------------

Among those who were achieving the target Kt/V, we compared the characteristics of patients using incremental PD prescriptions with those using full-dose PD. We also compared both groups with those not achieving the target. The normality of continuous variables was tested with the Shapiro-Wilk test, and verified with a Quantile-Quantile Plot (QQ plot). Normal continuous variables were compared using a *t* test. Nonnormal continuous variables were compared using the nonparametric Mann-Whitney *U* test. Binary variables were compared using the Pearson chi-square test.

Results {#section27-2054358116679131}
=======

Data were collected on all 124 patients on the PD program in June and July 2013. Demographic data are shown in [Table 1](#table1-2054358116679131){ref-type="table"}. Residual renal function was present in 105 (85%) patients with the renal Kt/V ranging from 0.05 to 2.82 per week. APD was used by 114 patients (92%) and CAPD by 10 (8%).

###### 

Basic Demographic Details on 124 Patients.

![](10.1177_2054358116679131-table1)

  ----------------------- -----------------
  Number of patients      124
  Age ± SD (y)            63 ± 15
  Male:female (%)         72:52 (58%:42%)
  Diabetic (%)            47 (38%)
  Weight ± SD (kg)        78.9 ± 19
  Anuric (%)              19 (15%)
  Previous hemodialysis   41 (33%)
  Time on PD ± SD (mo)    22 ± 22
  ----------------------- -----------------

*Note.* PD = peritoneal dialysis.

Of the 124 patients, 106 (86%) had Kt/V \>1.7 per week and 18 (14%) did not achieve this target. Of the 106 patients with Kt/V \>1.7 per week, 54 (51%) were on incremental PD and 52 (49%) were on full-dose PD prescriptions. These 52 patients comprised 29 (56%) who were dependent on residual renal function to achieve the target Kt/V and 23 (44%) who achieved the target independent of renal function ([Figure 1](#fig1-2054358116679131){ref-type="fig"}). Of the 18 not achieving a Kt/V of 1.7 per week, 14 were on full-dose prescriptions and 4 on low-dose prescriptions. The patients achieving target Kt/V using incremental PD were compared with those achieving it on standard prescriptions. Compared with those on full-dose prescriptions, the incremental patients had of course significantly more residual renal function and less duration of time on PD. They did not differ significantly in age, weight, sex, previous exposure to hemodialysis, or prevalence of diabetes ([Table 2](#table2-2054358116679131){ref-type="table"}). It should be emphasized that these 2 populations are not being managed by 2 different strategies. The patients using incremental PD will be switched to full-dose PD once they lose residual renal function and the full-dose PD patients were almost all previously on incremental PD prescriptions. The patients not achieving the Kt/V target had similar characteristics to the full-dose PD patients, but both their peritoneal and renal clearances were significantly lower ([Table 2](#table2-2054358116679131){ref-type="table"}).

![Pie chart showing percentage of patients on incremental PD, on full-dose PD and achieving target clearance independent of (RRF), and on full-dose PD but requiring residual function to reach target and not achieving target.\
*Note.* Number of patients in parentheses. PD = peritoneal dialysis.](10.1177_2054358116679131-fig1){#fig1-2054358116679131}

###### 

Comparison Between Patients Achieving Target Kt/V 1.7 per Week Using Incremental PD, Those Achieving It Using Full-Dose Prescriptions, and Those Not at Target.

![](10.1177_2054358116679131-table2)

                                     Incremental PD with Kt/V \>1.7   Full-dose PD with Kt/V \>1.7                                        Not at target Kt/V
  ---------------------------------- -------------------------------- ------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------
  No. of patients (%)                54                               52                                                                  18
  Age ± SD                           64 ± 13                          62 ± 16                                                             62 ± 16
  No. of males (%)                   32 (59%)                         29 (56%)                                                            11 (62%)
  Time on PD ± SD (mo)               15 ± 14                          27 ± 26[\*](#table-fn3-2054358116679131){ref-type="table-fn"}       28 ± 30[\*\*](#table-fn4-2054358116679131){ref-type="table-fn"}
  Weight ± SD (kg)                   77 ± 20                          80 ± 19                                                             81 ± 18
  No. with diabetes (%)              21 (38%)                         19 (37%)                                                            7 (38%)
  No. with previous HD (%)           13 (24%)                         21 (40%)                                                            7 (38%)
  Serum Cr ± SD (µmol/L)             625 ± 225                        840 ± 247^[†](#table-fn5-2054358116679131){ref-type="table-fn"}^    830 ± 299^[‡](#table-fn6-2054358116679131){ref-type="table-fn"}^
  Renal Cr clearance ± SD (mL/min)   6.2 ± 3.4                        2.7 ± 2.4^[†](#table-fn5-2054358116679131){ref-type="table-fn"}^    1.9 ± 3.0^[†](#table-fn5-2054358116679131){ref-type="table-fn"}^
  Renal Kt/V per week ± SD           1.2 ± 0.6                        0.6 ± 0.5^[†](#table-fn5-2054358116679131){ref-type="table-fn"}^    0.2 ± 0.3~[†](#table-fn5-2054358116679131){ref-type="table-fn"}[§](#table-fn7-2054358116679131){ref-type="table-fn"}~
  Peritoneal Kt/V per week ± SD      1.15 ± 0.3                       1.62 ± 0.4^[†](#table-fn5-2054358116679131){ref-type="table-fn"}^   1.36 ± 0.3[\*\*](#table-fn4-2054358116679131){ref-type="table-fn"}

*Note.* PD = peritoneal dialysis; Cr = creatinine; HD = hemodialysis.

*p* \< 0.001 compared to incremental PD.

*p* \< 0.05 compared to incremental PD.

*p* \< 0.0001 compared to incremental PD.

*p* \< 0.05 compared to full dose PD.

*p* \< 0.005 compared to full dose PD.

Of the 114 APD patients, 50 (43.8%) were on Incremental PD and their prescriptions comprised being "day dry" in 34 (68%), having at least 1 night off cycling each week in 6 (12%) and being both "day dry" and having at least 1 night off in 10 (20%) ([Figure 2](#fig2-2054358116679131){ref-type="fig"}). "Day dry" APD typically comprised 10 L of PD solution delivered over 8 to 9 hours each night with an initial dwell volumes of 1.5 to 2.0 L and with a mix of tidal and nontidal prescriptions.

![Pie chart showing distribution of incremental APD prescriptions.\
*Note.* Number of patients in parentheses. APD = automated peritoneal dialysis.](10.1177_2054358116679131-fig2){#fig2-2054358116679131}

Of the 10 CAPD patients, 4 (40%) were on Incremental PD and their prescriptions comprised 3 exchanges a day in 3 patients and 2 exchanges a day in 1 patient; one of the patients on 3 exchanges a day used 1.5-L dwell volumes.

The mean and median total Kt/V in the 124 patients was 2.15 (±0.5) and 2.05, respectively. The mean and median renal Kt/V was 0.78 (± 0.6) and 0.75, respectively, with a range from 0 to 2.82. The mean and median residual renal clearances were 41 ± 35 and 34 L/week per 1.73 meter squared body surface area (range, 0-141). These are equivalent to 4.1 ± 3.5 and 3.4 mL/min per 1.73 meter squared body surface area, respectively.

In the Incremental PD patients, the mean and median total Kt/V was 2.30 (±0.5) and 2.23, respectively. The mean and median peritoneal Kt/V was 1.15 (±0.30) and 1.10, respectively. The mean and median renal Kt/V was 1.2 (±0.6) and 1.00, respectively, with a range from 0.21 to 2.82.

Peritonitis rates for the 3 years prior to the study (2010, 2011, and 2012), during which incremental PD was being practiced, were 1 per 35, 25, and 40 months, respectively, and for 2013, the year of the study, the peritonitis rate was 1 per 44 months. One- and 3-year patient survivals for PD patients initiating PD at our center between 2007 and 2011 were 91% and 67%, respectively, and were not significantly different from expected survivals or from those in Canada as a whole ([Table 3](#table3-2054358116679131){ref-type="table"}).^[@bibr14-2054358116679131]^

###### 

Patient Survival for Patients Initiating PD 2007-2011 With Follow-Up Until End of 2011 in LHSC Compared With Province of Ontario and With Canada as a Whole.

![](10.1177_2054358116679131-table3)

                     1 year                                                                   3 years
  ------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------
  LHSC               91%                                                                      67%
  LHSC expected      93%^[a](#table-fn9-2054358116679131){ref-type="table-fn"}^ (*P* = .83)   70%^[a](#table-fn9-2054358116679131){ref-type="table-fn"}^ (*P* = .73)
  Ontario            91%                                                                      69%
  Ontario expected   92%^[a](#table-fn9-2054358116679131){ref-type="table-fn"}^ (*P* = .91)   70%^[a](#table-fn9-2054358116679131){ref-type="table-fn"}^ (*P* = .89)
  Canada             92%                                                                      70%

*Note.* PD = peritoneal dialysis; LHSC = London Health Sciences Center.

Differences nonsignificant.

Discussion {#section28-2054358116679131}
==========

The concept of incremental PD has been discussed in the literature for almost 2 decades. It is referenced as an option in a number of prominent clinical guideline and practice recommendations.^[@bibr1-2054358116679131],[@bibr13-2054358116679131]^ However, most of the reports of its use involve small numbers of patients, ranging from 5 to 25, mainly involve CAPD, and occur in the context of deliberate early initiation of dialysis, a practice which has been called into question after a recent large randomized controlled trial showing no benefit.^[@bibr5-2054358116679131][@bibr6-2054358116679131][@bibr7-2054358116679131][@bibr8-2054358116679131]-[@bibr9-2054358116679131],[@bibr17-2054358116679131]^ There are no descriptions of its systematic use in a large contemporary PD population or in a population predominantly treated with APD. Our center has routinely practiced an incremental strategy in all PD patients for over a decade in a large, primarily APD-based program which manages more than 100 patients. We show that in our center, incremental PD is feasible and associated with rates of peritonitis that compare favorably with the International Society of Peritoneal Dialysis target of no more than 1 episode every 18 months^[@bibr18-2054358116679131]^ and with patient survival similar to those seen in other Canadian PD centers.^[@bibr19-2054358116679131]^ The impact of incremental PD on clinical practice and the patient experience is apparent in that more than 40% of the patients were able to achieve clearance targets while using a less onerous low peritoneal clearance prescription.

A comment should be made about the 14% of patients not reaching the Kt/V target. In any cross-sectional review, there will always be patients who are below the clearance target and who then have their prescription adjusted and clearances remeasured. This is more likely to occur in patients with less or no residual renal function as was the case in this study. There are other cases where a decision is made in consultation with the patient to accept a lower clearance because the extra volumes of solution or procedures required to deliver higher clearance are not tolerated by, or acceptable to, the patient. This is especially so in older frailer patients where the potential disadvantages of increasing the prescription may outweigh the potential benefits.

Incremental PD has become increasingly relevant with the worldwide trend to initiate chronic dialysis at gradually greater levels of renal function over the past 2 decades.^[@bibr11-2054358116679131],[@bibr12-2054358116679131]^ The median estimated glomerular filtration rate initiating dialysis in North America has been reported to be greater than 10 mL/min.^[@bibr11-2054358116679131]^ However, a recent randomized controlled trial suggests there is no benefit to elective early initiation, and this trend may reverse.^[@bibr17-2054358116679131]^ Our center did not routinely practice early initiation of dialysis. The mean renal Kt/V in the patient population described here was 0.75 per week, equivalent to a urea clearance of about 3 mL/min and the mean residual renal clearance measured as the average of renal urea and creatinine clearance was just 4.1 mL/min. In those on incremental PD, the mean residual renal clearance was 6 mL/min. The patient population described did not therefore have notably high levels of residual renal function. Despite this, 44% of patients were able to receive an incremental PD prescription.

There are some clear advantages to the use of incremental PD. First, the PD prescription is less onerous with specifically less need for day dwells in those on APD and less need for large dwell volumes for those on both CAPD and APD. The result is greater simplicity and less workload for the patient or their caregivers. It is also likely that with less use of day dwells and of large dwell volumes, there will be a lower likelihood of the symptoms and complications associated with raised intraperitoneal volume and intra-abdominal pressure. Higher dwell volumes have been associated with more adverse mechanical symptoms in a randomized controlled trial.^[@bibr20-2054358116679131]^

For many patients, the benefit of incremental PD is not transient because the time course of residual renal function loss is very variable.^[@bibr21-2054358116679131][@bibr22-2054358116679131]-[@bibr23-2054358116679131]^ Incremental PD can be practiced for years, often until the patient is transplanted or switched to hemodialysis or dies from an unrelated cause. In this study, the patients on incremental PD prescriptions had already been on PD for a mean of 15 months and some had been on for more than 2 years. The impaired quality of life associated with chronic dialysis is well recognized, and so the benefit of making chronic PD easier for patients should not be underestimated. This is particularly the case in the elderly where transplant is less likely to be an option. In an era in which patient centered care is being emphasized, these considerations are central.^[@bibr24-2054358116679131]^

In addition, there are potential metabolic benefits to incremental PD. There is less exposure of the peritoneal membrane to glucose and glucose degradation products when less solution is used and there is less absorption of glucose systemically.^[@bibr25-2054358116679131]^ Recent randomized trials suggest that glucose-sparing PD solutions are associated with less hyperglycemia and hyperlipidemia in diabetic PD patients.^[@bibr25-2054358116679131],[@bibr26-2054358116679131]^ One might also speculate that less glucose exposure will decrease the risk of progressive obesity in PD patients.^[@bibr25-2054358116679131]^

Another advantage is that incremental PD prescriptions are less costly than standard ones, because less solution is required. In programs such as ours where relatively more expensive icodextrin solution is commonly used for day dwells in APD patients, the cost savings are considerable. In Canada, prices of PD solutions are not published and vary between centers, but the addition of a 2-L icodextrin day dwell to a standard 10-L glucose solution APD prescription typically raises the cost about 15% to 20%. Similarly, CAPD with 3 dwells costs 25% less than CAPD with 4 dwells daily.

There are some challenges associated with the use of incremental PD. First, it requires regular monitoring of residual renal function as its rate of loss is unpredictable. Our center measures renal function every 3 months in patients on incremental prescriptions. An alternative might be to measure it every 6 months and also if there is a change in the patient's health or an intercurrent illness likely to lead to a fall in (RRF). Second, patients who start PD with an incremental prescription may find it challenging to transition to a more onerous full prescription. This is hardly an argument against doing incremental PD, but it is appropriate to warn the patient in advance that such a transition may eventually be required. In practice, many patients never have to make this transition because of transplant, switch to hemodialysis, or death.

It should be noted that of the 52 patients achieving target Kt/V on full prescriptions, more than half were still dependent on residual renal function to do so. These patients are not doing incremental PD by our definition in that they receive a "full" PD prescription. Without residual renal function, these patients would have required a more aggressive prescription with higher dwell volumes or more day dwells or more frequent cycles. These patients also receive some of the same benefits of those on incremental PD---a less onerous prescription, less glucose exposure, less cost---although to a lesser degree. They also need regular monitoring of their residual renal clearance.

It is unlikely that an incremental PD strategy will ever be compared with an approach that uses full-dose PD from the start in a randomized controlled trial. The failure of previous randomized trials to show benefit for higher peritoneal clearance regimens makes such a study improbable. Rather, the rationale for incremental PD rests on deductions from a number of well-proven premises. First, it has been well shown that, within the usual therapeutic range, higher peritoneal clearances are not associated with improved outcomes.^[@bibr17-2054358116679131],[@bibr27-2054358116679131]^ Second, renal clearance is associated with superior outcomes in a way that equivalent amounts of peritoneal clearance are not.^[@bibr15-2054358116679131],[@bibr28-2054358116679131]^ It is a reasonable conclusion from this that if 2 patients have the same total clearance but one derives it from a mix of renal and peritoneal clearance while the other has it from peritoneal clearance alone, then the former scenario is associated with better survival. A patient receiving incremental PD is therefore unlikely to be disadvantaged relative to the same patient receiving a higher dose of peritoneal clearance. Notwithstanding this, we have presented here our PD patient survival rates, compared with nationwide results, and shown that there is no difference.

Conclusion {#section29-2054358116679131}
==========

In an era in which patient-centered care is being strongly emphasized, changes in clinical practice that make dialysis easier for patients without having an adverse effect on outcomes and with lower cost deserve attention.^[@bibr24-2054358116679131]^ Incremental PD is an example of such a strategy and should be widely considered.
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